SlideShare ist ein Scribd-Unternehmen logo
1 von 2
Downloaden Sie, um offline zu lesen
Practice Questions Set For the Second Quiz

1.   A 70-kg volunteer is given an intravenous dose of an antibiotic, and serum drug concentrations
     were determined at 2 hours and 5 hours after administration. The drug concentrations were 1.2
     and 0.3 g/mL, respectively. What is the biologic half-life for this drug, assuming first-order
     elimination kinetics?
2.   A 50-kg woman was given a single IV dose of an antibacterial drug at a dose level of 6 mg/kg. Blood
     samples were taken at various time intervals. The concentration of the drug (C p) was determined
     in the plasma fraction of each blood sample and the following data were obtained:

                                           t (hr)    C p (g/mL)
                                           0.25         8.21
                                           0.50         7.87
                                           1.00         7.23
                                           3.00         5.15
                                           6.00         3.09
                                           12.0         1.11
                                           18.0         0.40
a. What are the values for V D, k, and t 1/2 for this drug?
b. This antibacterial agent is not effective at a plasma concentration of less than 2 g/mL. What is the
       duration of activity for this drug?
c. How long would it take for 99.9% of this drug to be eliminated?
d. If the dose of the antibiotic were doubled exactly, what would be the increase in duration of activity?

3.   A new drug was given in a single intravenous dose of 200 mg to an 80-kg adult male patient. After 6
     hours, the plasma drug concentration of drug was 1.5 mg/100 mL of plasma. Assuming that the
     apparent V D is 10% of body weight, compute the total amount of drug in the body fluids after 6
     hours. What is the half-life of this drug?

4.   A new antibiotic drug was given in a single intravenous bolus of 4 mg/kg to five healthy male adults
     ranging in age from 23 to 38 years (average weight 75 kg). The pharmacokinetics of the plasma
     drug concentration–time curve for this drug fits a one-compartment model. The equation of the
     curve that best fits the data is


     Determine the following (assume units of g/mL for C p and hr for t):
     a. What is the t 1/2?
     b. What is the V D?
     c. What is the plasma level of the drug after 4 hours?
     d. How much drug is left in the body after 4 hours?
     e. Predict what body water compartment this drug might occupy and explain why you made this
     prediction.
     f. Assuming the drug is no longer effective when levels decline to less than 2 g/mL, when should
     you administer the next dose?
5.   Define the term apparent volume of distribution. What criteria are necessary for the measurement
     of the apparent volume of distribution to be useful in pharmacokinetic calculations?




Anas Bahnassi PhD RPh                       Pharmacokinetics                                     Fall 2012
Practice Questions Set For the Second Quiz

6.   A drug has an elimination t 1/2 of 6 hours and follows first-order kinetics. If a single 200-mg dose is
     given to an adult male patient (68 kg) by IV bolus injection, what percent of the dose is lost in 24
     hours?

7.   A rather intoxicated young man (75 kg, age 21) was admitted to a rehabilitation center. His blood
     alcohol content was found to be 210 mg%. Assuming the average elimination rate of alcohol is 10
     mL of ethanol per hour, how long would it take for his blood alcohol concentration to decline to
     less than the legal blood alcohol concentration of 100 mg%? (Hint: Alcohol is eliminated by zero-
     order kinetics.) The specific gravity of alcohol is 0.8. The apparent volume of distribution for alcohol
     is 60% of body weight.
8.   A single IV bolus injection containing 500 mg of cefamandole nafate (Mandol, Lilly) is given to an
     adult female patient (63 years, 55 kg) for a septicemic infection. The apparent volume of
     distribution is 0.1 L/kg and the elimination half-life is 0.75 hour. Assuming the drug is eliminated by
     first-order kinetics and may be described by a one-compartment model, calculate the following:
     a. The C p 0
     b. The amount of drug in the body 4 hours after the dose is given
     c. The time for the drug to decline to 0.5 g/mL, the minimum inhibitory concentration for
     streptococci

9.   If the amount of drug in the body declines from 100% of the dose (IV bolus injection) to 25% of the
     dose in 8 hours, what is the elimination half-life for this drug? (Assume first-order kinetics.)

10. A drug has an elimination half-life of 8 hours and follows first-order elimination kinetics. If a single
    600-mg dose is given to an adult female patient (62 kg) by rapid IV injection, what percent of the
    dose is eliminated (lost) in 24 hours assuming the apparent V D is 400 mL/kg? What is the expected
    plasma drug concentration (C p) at 24 hours postdose?

11. For drugs that follow the kinetics of a one-compartment open model, must the tissues and plasma
    have the same drug concentration? Why?
12. An adult male patient (age 35 years, weight 72 kg) with a urinary tract infection was given a single
    intravenous bolus of an antibiotic (dose = 300 mg). The patient was instructed to empty his bladder
    prior to being medicated. After dose administration, the patient saved his urine specimens for drug
    analysis. The urine specimens were analyzed for both drug content and sterility (lack of
    bacteriuria). The drug assays gave the following results:

                                   t (hr)             Amount of Drug in Urine (mg)
                                      0                              0
                                      4                            100
                                      8                             26
     a. Assuming first-order elimination, calculate the elimination half-life for the antibiotic in this
     patient.
     b. What are the practical problems in obtaining valid urinary drug excretion data for the
     determination of the drug elimination half-life?




Anas Bahnassi PhD RPh                         Pharmacokinetics                                       Fall 2012

Weitere ähnliche Inhalte

Was ist angesagt?

Clinical Pharmacokinetics-II [dosing of drugs, tdm]
Clinical Pharmacokinetics-II [dosing of drugs, tdm]Clinical Pharmacokinetics-II [dosing of drugs, tdm]
Clinical Pharmacokinetics-II [dosing of drugs, tdm]
BADAR UDDIN UMAR
 
Clinical pharmacokinetics and its application
Clinical pharmacokinetics and its applicationClinical pharmacokinetics and its application
Clinical pharmacokinetics and its application
pavithra vinayak
 
Bioavailability and Bioequivalence Studies
Bioavailability and Bioequivalence StudiesBioavailability and Bioequivalence Studies
Bioavailability and Bioequivalence Studies
Dr. Kunal Chitnis
 
Sterile formulations – large and small volume parenterals (1).pptx
Sterile formulations – large and small volume parenterals (1).pptxSterile formulations – large and small volume parenterals (1).pptx
Sterile formulations – large and small volume parenterals (1).pptx
Mamtanaagar1
 

Was ist angesagt? (20)

Clinical Pharmacokinetics-II [dosing of drugs, tdm]
Clinical Pharmacokinetics-II [dosing of drugs, tdm]Clinical Pharmacokinetics-II [dosing of drugs, tdm]
Clinical Pharmacokinetics-II [dosing of drugs, tdm]
 
Multiple Dosage regimen
Multiple Dosage regimenMultiple Dosage regimen
Multiple Dosage regimen
 
Drug Information Services
Drug Information ServicesDrug Information Services
Drug Information Services
 
Pharmacokinetics / Biopharmaceutics - Multi dosage regimens
Pharmacokinetics / Biopharmaceutics - Multi dosage regimensPharmacokinetics / Biopharmaceutics - Multi dosage regimens
Pharmacokinetics / Biopharmaceutics - Multi dosage regimens
 
Clinical pharmacokinetics and its application
Clinical pharmacokinetics and its applicationClinical pharmacokinetics and its application
Clinical pharmacokinetics and its application
 
Large volume parenterals
Large volume parenteralsLarge volume parenterals
Large volume parenterals
 
Drug distribution
Drug distributionDrug distribution
Drug distribution
 
Expt. 6 Bioassay of histamine using guinea pig ileum by matching method
Expt. 6 Bioassay of histamine using guinea pig ileum by matching methodExpt. 6 Bioassay of histamine using guinea pig ileum by matching method
Expt. 6 Bioassay of histamine using guinea pig ileum by matching method
 
Solid dosage forms (tablets)
Solid dosage forms (tablets)Solid dosage forms (tablets)
Solid dosage forms (tablets)
 
Adr reporting ppt
Adr reporting pptAdr reporting ppt
Adr reporting ppt
 
Evaluation of capules
Evaluation of capulesEvaluation of capules
Evaluation of capules
 
Bioavailability testing protocol
Bioavailability testing protocolBioavailability testing protocol
Bioavailability testing protocol
 
Bioavailability and Bioequivalence Studies
Bioavailability and Bioequivalence StudiesBioavailability and Bioequivalence Studies
Bioavailability and Bioequivalence Studies
 
Bioavailability ppt
Bioavailability pptBioavailability ppt
Bioavailability ppt
 
Large and small volume parenterals preparations
Large and small volume parenterals preparationsLarge and small volume parenterals preparations
Large and small volume parenterals preparations
 
Drug stability
Drug stabilityDrug stability
Drug stability
 
Sterile formulations – large and small volume parenterals (1).pptx
Sterile formulations – large and small volume parenterals (1).pptxSterile formulations – large and small volume parenterals (1).pptx
Sterile formulations – large and small volume parenterals (1).pptx
 
Comparison between conventional and sustained-release drugs
Comparison between conventional and sustained-release drugs Comparison between conventional and sustained-release drugs
Comparison between conventional and sustained-release drugs
 
Pharmacokinetics of multiple dosing
Pharmacokinetics of multiple dosingPharmacokinetics of multiple dosing
Pharmacokinetics of multiple dosing
 
Drug distribution & clearance
Drug distribution & clearanceDrug distribution & clearance
Drug distribution & clearance
 

Andere mochten auch

Pharmacokinetics lecture notes pharmacology
Pharmacokinetics lecture notes pharmacologyPharmacokinetics lecture notes pharmacology
Pharmacokinetics lecture notes pharmacology
Nunkoo Raj
 
Urinaryexcreation studies
Urinaryexcreation studiesUrinaryexcreation studies
Urinaryexcreation studies
Sonam Gandhi
 
Clinical pharmaco kinetics 1 bioavailability, 1st pass, renal clearance 2011
Clinical pharmaco kinetics 1 bioavailability, 1st pass, renal clearance 2011Clinical pharmaco kinetics 1 bioavailability, 1st pass, renal clearance 2011
Clinical pharmaco kinetics 1 bioavailability, 1st pass, renal clearance 2011
Muhammad Saim
 
Clinical Pharmacokinetics-I [half life, order of kinetics, steady state]
Clinical Pharmacokinetics-I [half life, order of kinetics, steady state]Clinical Pharmacokinetics-I [half life, order of kinetics, steady state]
Clinical Pharmacokinetics-I [half life, order of kinetics, steady state]
BADAR UDDIN UMAR
 

Andere mochten auch (15)

Pharmacokinetics lecture notes pharmacology
Pharmacokinetics lecture notes pharmacologyPharmacokinetics lecture notes pharmacology
Pharmacokinetics lecture notes pharmacology
 
Urinaryexcreation studies
Urinaryexcreation studiesUrinaryexcreation studies
Urinaryexcreation studies
 
Pharmacokinetics -Auc - area under curve
Pharmacokinetics -Auc -  area under curvePharmacokinetics -Auc -  area under curve
Pharmacokinetics -Auc - area under curve
 
Pharmacokinetics: Laboratory
Pharmacokinetics: LaboratoryPharmacokinetics: Laboratory
Pharmacokinetics: Laboratory
 
Clinical pharmaco kinetics 1 bioavailability, 1st pass, renal clearance 2011
Clinical pharmaco kinetics 1 bioavailability, 1st pass, renal clearance 2011Clinical pharmaco kinetics 1 bioavailability, 1st pass, renal clearance 2011
Clinical pharmaco kinetics 1 bioavailability, 1st pass, renal clearance 2011
 
Pharmacokinetics & Its clinical importance
Pharmacokinetics & Its clinical importancePharmacokinetics & Its clinical importance
Pharmacokinetics & Its clinical importance
 
Factors Affecting Protein-Binding of Drugs
Factors Affecting Protein-Binding of DrugsFactors Affecting Protein-Binding of Drugs
Factors Affecting Protein-Binding of Drugs
 
Pharmacokinetics: Lecture two
Pharmacokinetics: Lecture twoPharmacokinetics: Lecture two
Pharmacokinetics: Lecture two
 
Clearance Mechanism (Biopharmaceutics)
Clearance Mechanism (Biopharmaceutics)Clearance Mechanism (Biopharmaceutics)
Clearance Mechanism (Biopharmaceutics)
 
Protein binding of drugs
Protein binding of drugsProtein binding of drugs
Protein binding of drugs
 
one compartment model ppt
one compartment model pptone compartment model ppt
one compartment model ppt
 
Clinical Pharmacokinetics-I [half life, order of kinetics, steady state]
Clinical Pharmacokinetics-I [half life, order of kinetics, steady state]Clinical Pharmacokinetics-I [half life, order of kinetics, steady state]
Clinical Pharmacokinetics-I [half life, order of kinetics, steady state]
 
Pharmacodynamics PPT
Pharmacodynamics PPTPharmacodynamics PPT
Pharmacodynamics PPT
 
Compartment Modelling
Compartment ModellingCompartment Modelling
Compartment Modelling
 
Pharmacokinetics - drug absorption, drug distribution, drug metabolism, drug ...
Pharmacokinetics - drug absorption, drug distribution, drug metabolism, drug ...Pharmacokinetics - drug absorption, drug distribution, drug metabolism, drug ...
Pharmacokinetics - drug absorption, drug distribution, drug metabolism, drug ...
 

Ähnlich wie Problem Set One

A comparative bioavailability study of aceclofenac products in healthy human ...
A comparative bioavailability study of aceclofenac products in healthy human ...A comparative bioavailability study of aceclofenac products in healthy human ...
A comparative bioavailability study of aceclofenac products in healthy human ...
Alexander Decker
 
A comparative bioavailability study of aceclofenac products in healthy human ...
A comparative bioavailability study of aceclofenac products in healthy human ...A comparative bioavailability study of aceclofenac products in healthy human ...
A comparative bioavailability study of aceclofenac products in healthy human ...
Alexander Decker
 
Biological assay, drug assay, Bioassay of Insulin
Biological assay, drug assay, Bioassay of InsulinBiological assay, drug assay, Bioassay of Insulin
Biological assay, drug assay, Bioassay of Insulin
PradyumnaGhosal
 

Ähnlich wie Problem Set One (20)

Pharacokinetics power point for pharmacy
Pharacokinetics power point  for pharmacyPharacokinetics power point  for pharmacy
Pharacokinetics power point for pharmacy
 
Yazeed CALCULATIONS.pdf
Yazeed CALCULATIONS.pdfYazeed CALCULATIONS.pdf
Yazeed CALCULATIONS.pdf
 
Pharmacokinetic Models
Pharmacokinetic ModelsPharmacokinetic Models
Pharmacokinetic Models
 
Clinical pharmacokinetics
Clinical pharmacokineticsClinical pharmacokinetics
Clinical pharmacokinetics
 
STUDIES ON THE CHRONIC TOXICITY OF CHLOROQUINE 1948
STUDIES ON THE CHRONIC TOXICITY OF CHLOROQUINE 1948STUDIES ON THE CHRONIC TOXICITY OF CHLOROQUINE 1948
STUDIES ON THE CHRONIC TOXICITY OF CHLOROQUINE 1948
 
A comparative bioavailability study of aceclofenac products in healthy human ...
A comparative bioavailability study of aceclofenac products in healthy human ...A comparative bioavailability study of aceclofenac products in healthy human ...
A comparative bioavailability study of aceclofenac products in healthy human ...
 
A comparative bioavailability study of aceclofenac products in healthy human ...
A comparative bioavailability study of aceclofenac products in healthy human ...A comparative bioavailability study of aceclofenac products in healthy human ...
A comparative bioavailability study of aceclofenac products in healthy human ...
 
PK- Basic terminologies.pptx
PK- Basic terminologies.pptxPK- Basic terminologies.pptx
PK- Basic terminologies.pptx
 
2. Basic Phk-IV and EV.pptx
2. Basic Phk-IV and EV.pptx2. Basic Phk-IV and EV.pptx
2. Basic Phk-IV and EV.pptx
 
Pharmacokinetic models
Pharmacokinetic modelsPharmacokinetic models
Pharmacokinetic models
 
1612188029641020.pptx
1612188029641020.pptx1612188029641020.pptx
1612188029641020.pptx
 
Pharma co kinetics compartmental modeling
Pharma co kinetics compartmental modeling Pharma co kinetics compartmental modeling
Pharma co kinetics compartmental modeling
 
ReviewonCeftriaxone.pdf
ReviewonCeftriaxone.pdfReviewonCeftriaxone.pdf
ReviewonCeftriaxone.pdf
 
multiple-dosage-regimen.pdf
multiple-dosage-regimen.pdfmultiple-dosage-regimen.pdf
multiple-dosage-regimen.pdf
 
Toxicokinetics in preclinical studies by Priyabrata Panda
Toxicokinetics in preclinical studies by Priyabrata PandaToxicokinetics in preclinical studies by Priyabrata Panda
Toxicokinetics in preclinical studies by Priyabrata Panda
 
Calculation of the plasma drug levels after a single dose IVinfusion..pptx
Calculation of the plasma drug levels after a single dose IVinfusion..pptxCalculation of the plasma drug levels after a single dose IVinfusion..pptx
Calculation of the plasma drug levels after a single dose IVinfusion..pptx
 
Biological assay, drug assay, Bioassay of Insulin
Biological assay, drug assay, Bioassay of InsulinBiological assay, drug assay, Bioassay of Insulin
Biological assay, drug assay, Bioassay of Insulin
 
Multi compartment models
Multi compartment models Multi compartment models
Multi compartment models
 
Pharmacokinetics / Biopharmaceutics - Multi compartment IV bolus
Pharmacokinetics / Biopharmaceutics - Multi compartment IV bolusPharmacokinetics / Biopharmaceutics - Multi compartment IV bolus
Pharmacokinetics / Biopharmaceutics - Multi compartment IV bolus
 
poster v5 (1)
poster v5 (1)poster v5 (1)
poster v5 (1)
 

Mehr von Anas Bahnassi أنس البهنسي

Pharmacy Practice: Lecture one: Medication Management Cycle Part One
Pharmacy Practice: Lecture one: Medication Management Cycle Part OnePharmacy Practice: Lecture one: Medication Management Cycle Part One
Pharmacy Practice: Lecture one: Medication Management Cycle Part One
Anas Bahnassi أنس البهنسي
 

Mehr von Anas Bahnassi أنس البهنسي (20)

Lecture nine cardiovascular_emeregencies
Lecture nine cardiovascular_emeregenciesLecture nine cardiovascular_emeregencies
Lecture nine cardiovascular_emeregencies
 
Urinary Tract Infections
Urinary Tract InfectionsUrinary Tract Infections
Urinary Tract Infections
 
Pneumonia
PneumoniaPneumonia
Pneumonia
 
Influenza
InfluenzaInfluenza
Influenza
 
Acute bronchitis
Acute bronchitisAcute bronchitis
Acute bronchitis
 
Sinusitis
SinusitisSinusitis
Sinusitis
 
Streptococccal sore throat
Streptococccal sore throatStreptococccal sore throat
Streptococccal sore throat
 
Acute Otitis Media
Acute Otitis Media Acute Otitis Media
Acute Otitis Media
 
Principles of infectious diseases
Principles of infectious diseasesPrinciples of infectious diseases
Principles of infectious diseases
 
Lecture three management cycle Part 3
Lecture three management cycle Part 3Lecture three management cycle Part 3
Lecture three management cycle Part 3
 
Lecture two management cycle Part: 2
Lecture two management cycle Part: 2Lecture two management cycle Part: 2
Lecture two management cycle Part: 2
 
Pharmacy Practice: Lecture one: Medication Management Cycle Part One
Pharmacy Practice: Lecture one: Medication Management Cycle Part OnePharmacy Practice: Lecture one: Medication Management Cycle Part One
Pharmacy Practice: Lecture one: Medication Management Cycle Part One
 
Osteoarthritis
OsteoarthritisOsteoarthritis
Osteoarthritis
 
Juvenile idiopathic arthritis
Juvenile idiopathic arthritisJuvenile idiopathic arthritis
Juvenile idiopathic arthritis
 
Rheumatoid arthritis Part 2
Rheumatoid arthritis Part 2Rheumatoid arthritis Part 2
Rheumatoid arthritis Part 2
 
Rheumatoid Arthritis Part !
Rheumatoid Arthritis Part !Rheumatoid Arthritis Part !
Rheumatoid Arthritis Part !
 
Pharmacotherapy of Diabetes: Part 2
Pharmacotherapy of Diabetes: Part 2Pharmacotherapy of Diabetes: Part 2
Pharmacotherapy of Diabetes: Part 2
 
Role of community pharmacists in diabetes management
Role of community pharmacists in diabetes managementRole of community pharmacists in diabetes management
Role of community pharmacists in diabetes management
 
Diabetes Care: Part One
Diabetes Care: Part OneDiabetes Care: Part One
Diabetes Care: Part One
 
Premixed insulin dosing in actual practice
Premixed insulin dosing in actual practicePremixed insulin dosing in actual practice
Premixed insulin dosing in actual practice
 

Kürzlich hochgeladen

Jual Obat Aborsi Hongkong ( Asli No.1 ) 085657271886 Obat Penggugur Kandungan...
Jual Obat Aborsi Hongkong ( Asli No.1 ) 085657271886 Obat Penggugur Kandungan...Jual Obat Aborsi Hongkong ( Asli No.1 ) 085657271886 Obat Penggugur Kandungan...
Jual Obat Aborsi Hongkong ( Asli No.1 ) 085657271886 Obat Penggugur Kandungan...
ZurliaSoop
 
Activity 01 - Artificial Culture (1).pdf
Activity 01 - Artificial Culture (1).pdfActivity 01 - Artificial Culture (1).pdf
Activity 01 - Artificial Culture (1).pdf
ciinovamais
 

Kürzlich hochgeladen (20)

PROCESS RECORDING FORMAT.docx
PROCESS      RECORDING        FORMAT.docxPROCESS      RECORDING        FORMAT.docx
PROCESS RECORDING FORMAT.docx
 
This PowerPoint helps students to consider the concept of infinity.
This PowerPoint helps students to consider the concept of infinity.This PowerPoint helps students to consider the concept of infinity.
This PowerPoint helps students to consider the concept of infinity.
 
General Principles of Intellectual Property: Concepts of Intellectual Proper...
General Principles of Intellectual Property: Concepts of Intellectual  Proper...General Principles of Intellectual Property: Concepts of Intellectual  Proper...
General Principles of Intellectual Property: Concepts of Intellectual Proper...
 
Unit-IV; Professional Sales Representative (PSR).pptx
Unit-IV; Professional Sales Representative (PSR).pptxUnit-IV; Professional Sales Representative (PSR).pptx
Unit-IV; Professional Sales Representative (PSR).pptx
 
How to Create and Manage Wizard in Odoo 17
How to Create and Manage Wizard in Odoo 17How to Create and Manage Wizard in Odoo 17
How to Create and Manage Wizard in Odoo 17
 
Holdier Curriculum Vitae (April 2024).pdf
Holdier Curriculum Vitae (April 2024).pdfHoldier Curriculum Vitae (April 2024).pdf
Holdier Curriculum Vitae (April 2024).pdf
 
Asian American Pacific Islander Month DDSD 2024.pptx
Asian American Pacific Islander Month DDSD 2024.pptxAsian American Pacific Islander Month DDSD 2024.pptx
Asian American Pacific Islander Month DDSD 2024.pptx
 
2024-NATIONAL-LEARNING-CAMP-AND-OTHER.pptx
2024-NATIONAL-LEARNING-CAMP-AND-OTHER.pptx2024-NATIONAL-LEARNING-CAMP-AND-OTHER.pptx
2024-NATIONAL-LEARNING-CAMP-AND-OTHER.pptx
 
Understanding Accommodations and Modifications
Understanding  Accommodations and ModificationsUnderstanding  Accommodations and Modifications
Understanding Accommodations and Modifications
 
UGC NET Paper 1 Mathematical Reasoning & Aptitude.pdf
UGC NET Paper 1 Mathematical Reasoning & Aptitude.pdfUGC NET Paper 1 Mathematical Reasoning & Aptitude.pdf
UGC NET Paper 1 Mathematical Reasoning & Aptitude.pdf
 
Food safety_Challenges food safety laboratories_.pdf
Food safety_Challenges food safety laboratories_.pdfFood safety_Challenges food safety laboratories_.pdf
Food safety_Challenges food safety laboratories_.pdf
 
Python Notes for mca i year students osmania university.docx
Python Notes for mca i year students osmania university.docxPython Notes for mca i year students osmania university.docx
Python Notes for mca i year students osmania university.docx
 
Mehran University Newsletter Vol-X, Issue-I, 2024
Mehran University Newsletter Vol-X, Issue-I, 2024Mehran University Newsletter Vol-X, Issue-I, 2024
Mehran University Newsletter Vol-X, Issue-I, 2024
 
Jual Obat Aborsi Hongkong ( Asli No.1 ) 085657271886 Obat Penggugur Kandungan...
Jual Obat Aborsi Hongkong ( Asli No.1 ) 085657271886 Obat Penggugur Kandungan...Jual Obat Aborsi Hongkong ( Asli No.1 ) 085657271886 Obat Penggugur Kandungan...
Jual Obat Aborsi Hongkong ( Asli No.1 ) 085657271886 Obat Penggugur Kandungan...
 
Key note speaker Neum_Admir Softic_ENG.pdf
Key note speaker Neum_Admir Softic_ENG.pdfKey note speaker Neum_Admir Softic_ENG.pdf
Key note speaker Neum_Admir Softic_ENG.pdf
 
Activity 01 - Artificial Culture (1).pdf
Activity 01 - Artificial Culture (1).pdfActivity 01 - Artificial Culture (1).pdf
Activity 01 - Artificial Culture (1).pdf
 
TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...
TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...
TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...
 
Basic Civil Engineering first year Notes- Chapter 4 Building.pptx
Basic Civil Engineering first year Notes- Chapter 4 Building.pptxBasic Civil Engineering first year Notes- Chapter 4 Building.pptx
Basic Civil Engineering first year Notes- Chapter 4 Building.pptx
 
Making communications land - Are they received and understood as intended? we...
Making communications land - Are they received and understood as intended? we...Making communications land - Are they received and understood as intended? we...
Making communications land - Are they received and understood as intended? we...
 
Mixin Classes in Odoo 17 How to Extend Models Using Mixin Classes
Mixin Classes in Odoo 17  How to Extend Models Using Mixin ClassesMixin Classes in Odoo 17  How to Extend Models Using Mixin Classes
Mixin Classes in Odoo 17 How to Extend Models Using Mixin Classes
 

Problem Set One

  • 1. Practice Questions Set For the Second Quiz 1. A 70-kg volunteer is given an intravenous dose of an antibiotic, and serum drug concentrations were determined at 2 hours and 5 hours after administration. The drug concentrations were 1.2 and 0.3 g/mL, respectively. What is the biologic half-life for this drug, assuming first-order elimination kinetics? 2. A 50-kg woman was given a single IV dose of an antibacterial drug at a dose level of 6 mg/kg. Blood samples were taken at various time intervals. The concentration of the drug (C p) was determined in the plasma fraction of each blood sample and the following data were obtained: t (hr) C p (g/mL) 0.25 8.21 0.50 7.87 1.00 7.23 3.00 5.15 6.00 3.09 12.0 1.11 18.0 0.40 a. What are the values for V D, k, and t 1/2 for this drug? b. This antibacterial agent is not effective at a plasma concentration of less than 2 g/mL. What is the duration of activity for this drug? c. How long would it take for 99.9% of this drug to be eliminated? d. If the dose of the antibiotic were doubled exactly, what would be the increase in duration of activity? 3. A new drug was given in a single intravenous dose of 200 mg to an 80-kg adult male patient. After 6 hours, the plasma drug concentration of drug was 1.5 mg/100 mL of plasma. Assuming that the apparent V D is 10% of body weight, compute the total amount of drug in the body fluids after 6 hours. What is the half-life of this drug? 4. A new antibiotic drug was given in a single intravenous bolus of 4 mg/kg to five healthy male adults ranging in age from 23 to 38 years (average weight 75 kg). The pharmacokinetics of the plasma drug concentration–time curve for this drug fits a one-compartment model. The equation of the curve that best fits the data is Determine the following (assume units of g/mL for C p and hr for t): a. What is the t 1/2? b. What is the V D? c. What is the plasma level of the drug after 4 hours? d. How much drug is left in the body after 4 hours? e. Predict what body water compartment this drug might occupy and explain why you made this prediction. f. Assuming the drug is no longer effective when levels decline to less than 2 g/mL, when should you administer the next dose? 5. Define the term apparent volume of distribution. What criteria are necessary for the measurement of the apparent volume of distribution to be useful in pharmacokinetic calculations? Anas Bahnassi PhD RPh Pharmacokinetics Fall 2012
  • 2. Practice Questions Set For the Second Quiz 6. A drug has an elimination t 1/2 of 6 hours and follows first-order kinetics. If a single 200-mg dose is given to an adult male patient (68 kg) by IV bolus injection, what percent of the dose is lost in 24 hours? 7. A rather intoxicated young man (75 kg, age 21) was admitted to a rehabilitation center. His blood alcohol content was found to be 210 mg%. Assuming the average elimination rate of alcohol is 10 mL of ethanol per hour, how long would it take for his blood alcohol concentration to decline to less than the legal blood alcohol concentration of 100 mg%? (Hint: Alcohol is eliminated by zero- order kinetics.) The specific gravity of alcohol is 0.8. The apparent volume of distribution for alcohol is 60% of body weight. 8. A single IV bolus injection containing 500 mg of cefamandole nafate (Mandol, Lilly) is given to an adult female patient (63 years, 55 kg) for a septicemic infection. The apparent volume of distribution is 0.1 L/kg and the elimination half-life is 0.75 hour. Assuming the drug is eliminated by first-order kinetics and may be described by a one-compartment model, calculate the following: a. The C p 0 b. The amount of drug in the body 4 hours after the dose is given c. The time for the drug to decline to 0.5 g/mL, the minimum inhibitory concentration for streptococci 9. If the amount of drug in the body declines from 100% of the dose (IV bolus injection) to 25% of the dose in 8 hours, what is the elimination half-life for this drug? (Assume first-order kinetics.) 10. A drug has an elimination half-life of 8 hours and follows first-order elimination kinetics. If a single 600-mg dose is given to an adult female patient (62 kg) by rapid IV injection, what percent of the dose is eliminated (lost) in 24 hours assuming the apparent V D is 400 mL/kg? What is the expected plasma drug concentration (C p) at 24 hours postdose? 11. For drugs that follow the kinetics of a one-compartment open model, must the tissues and plasma have the same drug concentration? Why? 12. An adult male patient (age 35 years, weight 72 kg) with a urinary tract infection was given a single intravenous bolus of an antibiotic (dose = 300 mg). The patient was instructed to empty his bladder prior to being medicated. After dose administration, the patient saved his urine specimens for drug analysis. The urine specimens were analyzed for both drug content and sterility (lack of bacteriuria). The drug assays gave the following results: t (hr) Amount of Drug in Urine (mg) 0 0 4 100 8 26 a. Assuming first-order elimination, calculate the elimination half-life for the antibiotic in this patient. b. What are the practical problems in obtaining valid urinary drug excretion data for the determination of the drug elimination half-life? Anas Bahnassi PhD RPh Pharmacokinetics Fall 2012